Skip to main navigation Skip to search Skip to main content

The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis

  • Matthew Wells
  • , Theresa Smith
  • , Robyn Domsic
  • , Aishwarya Anilkumar
  • , Tracy M Frech
  • , Ariane L Herrick
  • , Laura Hummers
  • , Ami A Shah
  • , Christopher P Denton
  • , Dinesh Khanna
  • , Shaney L Barratt
  • , John Pauling
  • North Bristol NHS Trust
  • University of Pittsburgh
  • Royal National Hospital for Rheumatic Diseases
  • Vanderbilt University
  • University of Manchester
  • Manchester Academic Health Science Centre
  • Salford Royal NHS Foundation Trust
  • John Hopkins University
  • University College London
  • Royal Free London NHS Foundation Trust
  • University of Michigan
  • University of Bristol
  • University of Bristol

Research output: Contribution to journalArticlepeer-review

7 Downloads (Pure)

Abstract

Objectives: Telangiectasia are common in SSc. We explored the relationship between the site and quantity of telangiectasia with disease characteristics in SSc, and the agreement between patient- and physician-reported quantification of telangiectasia. Methods: A retrospective analysis of a large, cross-sectional international SSc-related vasculopathy study was undertaken, including clinician and patient assessments of telangiectasia counts (0, 1–6, 7–15 or >15) in the face, forearms and hands. Relationships between telangiectasia count at each site, demographics and clinical features including calcinosis, digital ulceration (DU) and pulmonary arterial hypertension (PAH) were examined using proportional odds logistic regression. A binary logistic regression model examined the value of telangiectasia counts on the accuracy of identifying co-existent PAH. Concordance between clinician- and patient-reported telangiectasia counts at each anatomical site was tested. Results: Higher telangiectasia counts over the face and hands were associated with higher prevalence of calcinosis, DU and PAH in univariate analysis (P < 0.001–0.003). In multivariate analysis, the presence of PAH, DU and calcinosis were associated with higher facial telangiectasia (P < 0.05). The logistic regression model for the detection of PAH was enhanced with inclusion of telangiectasia count and site (area under the precision recall curve 0.824–0.875). Strength of agreement between clinician- and patient-reported telangiectasia counts were moderate for face and forearms (kappa 0.648 and 0.605 respectively, P < 0.001) and relatively weaker for hands (kappa 0.584, P < 0.001). Conclusion: The number of telangiectasia might be considered a complementary biomarker to the presence of vascular complications of SSc including PAH, DU and calcinosis. The anatomical regions and level of instruction provided for patient-reported count of telangiectasia need further optimization to be considered reliable and feasible. In addition, future work should consider correlations with nailfold capillaroscopic patterns.

Original languageEnglish
Article numberkeag267
Number of pages11
JournalRheumatology
Volume65
Issue number6
Early online date22 May 2026
DOIs
Publication statusPublished - 30 Jun 2026

Data Availability Statement

The data underlying this article cannot be shared publicly to
protect the privacy of individuals that participated in the study

Acknowledgements

The authors wish to thank the study participants and research coordinators based at each study site for their support for the original Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) validation study. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Funding

This work was supported by a grant from the US Department of Defence (Award Number W81XWH-18-1-0602) and the Scleroderma Clinical Trials Consortium. A.L.H. is supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). A.A.S. is supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH/NIAMS) K24 AR080217. The Johns Hopkins Scleroderma Center Research Registry is supported by the Johns Hopkins in Health initiative, the Nancy and Joachim Bchtle Precision Medicine Fund for Scleroderma, the Manugian Family Scholar, the Donald B. and Dorothy L. Stabler Foundation, the Chresanthe Staurulakis Memorial Fund, the Sara and Alex Othon Research Fund, and the NIH/NIAMS P30 AR070254.

Keywords

  • Raynaud’s syndrome
  • biomarkers
  • cardiovascular
  • quality of life
  • rare diseases
  • respiratory
  • scleroderma and related disorders
  • translational studies

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis'. Together they form a unique fingerprint.

Cite this